MA26660A1 - Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. - Google Patents

Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Info

Publication number
MA26660A1
MA26660A1 MA25684A MA25684A MA26660A1 MA 26660 A1 MA26660 A1 MA 26660A1 MA 25684 A MA25684 A MA 25684A MA 25684 A MA25684 A MA 25684A MA 26660 A1 MA26660 A1 MA 26660A1
Authority
MA
Morocco
Prior art keywords
propylcarbamate
phosphonooxy
aminophenyl
furanyl
tetrahydro
Prior art date
Application number
MA25684A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26660A1 publication Critical patent/MA26660A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA25684A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. MA26660A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
MA26660A1 true MA26660A1 (fr) 2004-12-20

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25684A MA26660A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Country Status (47)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1098898B1 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
WO2001025240A1 (fr) * 1999-10-06 2001-04-12 Tibotec Pharmaceuticals Ltd. HEXAHYDROFURO'2,3-B! FURAN-3-YL-N- {3'(1,3-BENZODIOXOL-5-YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL}CARBAMATE EN TANT QU'INHIBITEUR DE PROTEASE RETROVIRALE
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
CA2444597A1 (fr) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Inhibiteurs de fab i
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
CA2508792C (fr) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Composes heterocycliques, procedes de production de ceux-ci et utilisation de ceux-ci dans un traitement
WO2004082586A2 (fr) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
WO2004096287A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ, インコーポレイテッド キナーゼインヒビターホスホネート抱合体
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
ES2297467T3 (es) * 2003-09-30 2008-05-01 Tibotec Pharmaceuticals Ltd. Sulfonamidas de inhibicion de vhc.
WO2005044308A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Analogues phosphonates d'antimetabolites
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
DE602004019815D1 (de) 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
CA2568914C (fr) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Agents therapeutiques, et methodes de fabrication et d'utilisation
EP1778251B1 (fr) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Conjugues de phosphonate nucleosidique comme agents anti-vih
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
EP1973902A2 (fr) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. Agents therapeutiques et ses procédés de fabrication et d utilisation
EP2687533B1 (fr) 2006-07-20 2017-07-19 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de FAB I
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2262538B1 (fr) * 2008-03-12 2014-12-10 Nektar Therapeutics Conjugués oligomères-acides aminés
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EP2440200B8 (fr) 2009-06-08 2014-10-15 UCL Business PLC Traitement de l'hypertension portale au moyen de phénylacétate de l-ornithine
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
WO2011001383A1 (fr) * 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Forme cristalline de fosamprénavir calcium
CA2774483C (fr) * 2009-09-16 2014-11-18 Ranbaxy Laboratories Limited Procede pour preparer du fosamprenavir calcium
EP2507250A1 (fr) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
US20130211108A1 (en) * 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
EP2625162B1 (fr) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Procédés de fabrication d'acétate de phényle de l-ornithine
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
IN2012DE00082A (fr) 2012-01-10 2015-05-01 Council Scient Ind Res
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス, インコーポレイテッド L-オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる筋肉喪失の治療および予防
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
WO1999033792A2 (fr) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2000018384A2 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
CN1154491C (zh) * 1998-11-04 2004-06-23 法玛西雅厄普约翰美国公司 用于改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
WO2001038332A1 (fr) * 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides intervenant comme inhibiteurs de la protease du vih

Also Published As

Publication number Publication date
EP1240903A2 (fr) 2002-09-18
PA8477801A1 (es) 2000-05-24
AP2001002039A0 (en) 2001-03-31
EP1098898A1 (fr) 2001-05-16
IS5808A (is) 2001-01-12
IL140824A0 (en) 2002-02-10
HRP20010046A2 (en) 2002-02-28
SK285311B6 (sk) 2006-10-05
GC0000105A (en) 2005-06-29
PL345620A1 (en) 2002-01-02
ATE229964T1 (de) 2003-01-15
SV1999000096A (es) 2000-07-06
GT199900111A (es) 2001-01-05
NO20010282D0 (no) 2001-01-17
DE69904600T2 (de) 2003-11-13
EE200100038A (et) 2002-06-17
GB9815567D0 (en) 1998-09-16
US20030096795A1 (en) 2003-05-22
DK1098898T3 (da) 2003-04-07
EA200100053A1 (ru) 2001-08-27
CN1188422C (zh) 2005-02-09
JP2003521447A (ja) 2003-07-15
AU766056B2 (en) 2003-10-09
PL195736B1 (pl) 2007-10-31
ES2189450T3 (es) 2003-07-01
BG105253A (en) 2001-12-29
NO329676B1 (no) 2010-11-29
PE20000869A1 (es) 2000-09-08
DE69904600D1 (de) 2003-01-30
WO2000004033A1 (fr) 2000-01-27
HUP0103432A3 (en) 2003-01-28
CA2337857A1 (fr) 2000-01-27
NZ509291A (en) 2003-05-30
TNSN99145A1 (fr) 2005-11-10
KR100694721B1 (ko) 2007-03-15
BRPI9912156B1 (pt) 2016-07-26
IL140824A (en) 2004-09-27
PT1098898E (pt) 2003-04-30
TR200100111T2 (tr) 2002-02-21
CN1324363A (zh) 2001-11-28
ID28070A (id) 2001-05-03
BR9912156A (pt) 2001-04-10
HUP0103432A2 (hu) 2002-04-29
DZ2845A1 (fr) 2003-12-01
BRPI9912156B8 (pt) 2021-05-25
SK762001A3 (en) 2001-10-08
GEP20033030B (en) 2003-07-25
HK1034261A1 (en) 2001-10-19
EP1098898B1 (fr) 2002-12-18
AR019388A1 (es) 2002-02-13
CO5090836A1 (es) 2001-10-30
CZ2001219A3 (cs) 2001-07-11
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
ZA200100417B (en) 2002-02-27
CZ300447B6 (cs) 2009-05-20
TWI245770B (en) 2005-12-21
JO2114B1 (en) 2000-05-21
EP1240903A3 (fr) 2003-02-12
MY122323A (en) 2006-04-29
US6514953B1 (en) 2003-02-04
NO20010282L (no) 2001-03-07
EA003191B1 (ru) 2003-02-27
HU229700B1 (en) 2014-05-28
CA2337857C (fr) 2011-01-25
JP3437553B2 (ja) 2003-08-18
AU5037999A (en) 2000-02-07
OA11706A (en) 2005-01-13
YU3401A (sh) 2005-06-10

Similar Documents

Publication Publication Date Title
DE69904600D1 (de) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat
DZ2740A1 (fr) Catalyseurs de polymésation.
DZ2737A1 (fr) Catalyseurs de polymérisation.
NO995589D0 (no) Fremgangsmåte for å bestemme senderetning, samt radiosystem
BR9700369B1 (pt) compostos de dimetil-(3-aril-but-3- enil)-amina.
ITMI982247A0 (it) Procedimento per impermeabilizzare la pelle ottenuta mediante tale procedimento
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
ITTO950478A0 (it) Rotore per elicotteri.
ES1047984Y (es) Corchete de ortodoncia.
HN1999000113A (es) (3s) tetrahidro - 3 - funaril (15, 2r) - 3 - [[4 - aminofenil) sulfonil)] (isobutil) amino] - 1 - bencil - 2 (fosfonooxi) propilcarbamato de calcio.
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.
ES1030098Y (es) Tapa-casquillo nivelador, para somieres de ballestas.
AU8463098A (en) Process for preparing (2r,3s)-3-(substituted or unsubstituted phenyl)glycidamidecompounds by asymmetric amidation
KR950024792U (ko) 차량용 엘. 피. 지 캡(l. p. g cap)
ITBO970012A0 (it) Metodo per la formazione distrati di sigarette.
BR9611957A (pt) Di-hidrato de (2r,3s) -3- terc.- butoxicarbonilamino - 2 -hidroxi - 3 - fenilpropionato de 4,10 beta-diacetoxi - 2 - alfa-benzoiloxi-5beta, 20 - epoxi - 1 - hidroxi - 9 - oco - 19 - nor - ciclopropa[g]tax - 11eno - 13alfa - ila e processo para preparação do mesmo
ES1039039Y (es) Dardo de ventosas para juego de diana.
ES1037688Y (es) Dispositivo de ayuda para la expectoracion, no invasivo.
ES1036214Y (es) Sillita-carrito de paseo-mochila, para muñecos.
IT238487Y1 (it) Involucro esterno per piantine.
ES1040568Y (es) Instrumento de escritura.
ES1039379Y (es) Bigudi retenedor de humedad.
ITBO970443A0 (it) Tovagliolino mappa per parco giochi.
FR2766908B1 (fr) Module de ventilation, notamment pour veranda